

# Jack M Cuzick

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1158782/publications.pdf>

Version: 2024-02-01

328  
papers

29,399  
citations

9428

76  
h-index

6349

163  
g-index

338  
all docs

338  
docs citations

338  
times ranked

25547  
citing authors

#	ARTICLE	IF	CITATIONS
1	A case-control study to evaluate the impact of the breast screening programme on breast cancer incidence in England. <i>Cancer Medicine</i> , 2023, 12, 1878-1887.	1.3	8
2	Adherence to National Guidelines on Cervical Screening: A Population-Based Evaluation From a Statewide Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 626-630.	3.0	5
3	The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin?. <i>International Journal of Cancer</i> , 2022, 150, 73-79.	2.3	24
4	Clinical performance of methylation as a biomarker for cervical carcinoma <i>in situ</i> and cancer diagnosis: A worldwide study. <i>International Journal of Cancer</i> , 2022, 150, 290-302.	2.3	18
5	Dementia risk in a diverse population: A single-region nested case-control study in the East End of London. <i>Lancet Regional Health - Europe</i> , 2022, 15, 100321.	3.0	13
6	Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy. <i>European Journal of Cancer</i> , 2022, 164, 52-61.	1.3	0
7	Breast cancer risk stratification in women of screening age: Incremental effects of adding mammographic density, polygenic risk, and a gene panel. <i>Genetics in Medicine</i> , 2022, 24, 1485-1494.	1.1	23
8	DNA methylation testing with S5 for triage of high-risk HPV positive women. <i>International Journal of Cancer</i> , 2022, 151, 993-1004.	2.3	8
9	Effective methylation triage of HPV positive women with abnormal cytology in a middle-income country. <i>International Journal of Cancer</i> , 2021, 148, 1383-1393.	2.3	21
10	Adjunctive testing by cytology, p16/Ki67 dual-stained cytology or HPV16/18 E6 oncoprotein for the management of HPV16/18 screen-positive women. <i>International Journal of Cancer</i> , 2021, 148, 2264-2273.	2.3	4
11	A case-control study to evaluate the impact of the breast screening programme on mortality in England. <i>British Journal of Cancer</i> , 2021, 124, 736-743.	2.9	14
12	Calibration of CTS5 in Women With Early Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 338-339.	0.8	3
13	Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 126-135.	0.8	69
14	Estimated and projected burden of multiple sclerosis attributable to smoking and childhood and adolescent high body-mass index: a comparative risk assessment. <i>International Journal of Epidemiology</i> , 2021, 49, 2051-2057.	0.9	9
15	Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial. <i>British Journal of Cancer</i> , 2021, 124, 1373-1378.	2.9	3
16	A Randomized Comparison of Different Vaginal Self-sampling Devices and Urine for Human Papillomavirus Testing—Predictors 5.1. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 661-668.	1.1	38
17	Abstract PS18-10: Intratumoural heterogeneity in PgR expression: Molecular and prognostic significance. , 2021, , .		0
18	Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®. <i>Npj Breast Cancer</i> , 2021, 7, 15.	2.3	11

#	ARTICLE	IF	CITATIONS
19	Consistency of the S5 DNA methylation classifier in formalin-fixed biopsies versus corresponding exfoliated cells for the detection of pre-cancerous cervical lesions. <i>Cancer Medicine</i> , 2021, 10, 2668-2679.	1.3	3
20	The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 215-223.	1.1	10
21	Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma <i>in situ</i> : Results from the UK/ANZ DCIS Trial. <i>Clinical Cancer Research</i> , 2021, 27, 2861-2867.	3.2	9
22	Improving estimation of Parkinson's disease risk—the enhanced PREDICT-PD algorithm. <i>Npj Parkinson's Disease</i> , 2021, 7, 33.	2.5	13
23	Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries. <i>American Journal of Preventive Medicine</i> , 2021, 60, 478-487.	1.6	13
24	Burden of <i>Mycoplasma genitalium</i> and Bacterial Coinfections in a Population-Based Sample in New Mexico. <i>Sexually Transmitted Diseases</i> , 2021, 48, e186-e189.	0.8	4
25	The Relationship between Body Mass Index and Mammographic Density during a Premenopausal Weight Loss Intervention Study. <i>Cancers</i> , 2021, 13, 3245.	1.7	5
26	A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer Risk. <i>Cancers</i> , 2021, 13, 3303.	1.7	8
27	Performance of an affordable urine self-sampling method for human papillomavirus detection in Mexican women. <i>PLoS ONE</i> , 2021, 16, e0254946.	1.1	10
28	Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma <i>In Situ</i> : Results from the UK/ANZ DCIS Randomized Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5317-5324.	3.2	17
29	Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy. <i>Cancer Reports</i> , 2021, , e1535.	0.6	2
30	Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States. <i>Gynecologic Oncology</i> , 2021, 162, 555-559.	0.6	11
31	Clinical follow-up practices after cervical cancer screening by co-testing: A population-based study of adherence to U.S. guideline recommendations. <i>Preventive Medicine</i> , 2021, 153, 106770.	1.6	16
32	Optimising classification of Parkinson's disease based on motor, olfactory, neuropsychiatric and sleep features. <i>Npj Parkinson's Disease</i> , 2021, 7, 87.	2.5	4
33	Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review. <i>The Cochrane Library</i> , 2021, 2021, CD013091.	1.5	4
34	A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density. <i>International Journal of Cancer</i> , 2020, 146, 2122-2129.	2.3	38
35	Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study. <i>Clinical Cancer Research</i> , 2020, 26, 623-631.	3.2	10
36	Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 725-734.	1.2	30

#	ARTICLE	IF	CITATIONS
37	Impact of screening on cervical cancer incidence: A population-based case-control study in the United States. <i>International Journal of Cancer</i> , 2020, 147, 887-896.	2.3	20
38	Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. <i>Lancet, The</i> , 2020, 395, 117-122.	6.3	128
39	Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years. <i>Breast Cancer Research</i> , 2020, 22, 101.	2.2	19
40	A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States. <i>Gynecologic Oncology</i> , 2020, 159, 344-353.	0.6	9
41	Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial. <i>Breast</i> , 2020, 54, 216-221.	0.9	12
42	A Pooled Analysis to Compare the Clinical Characteristics of Human Papillomavirus-positive and -Negative Cervical Precancers. <i>Cancer Prevention Research</i> , 2020, 13, 829-840.	0.7	6
43	Key steps for effective breast cancer prevention. <i>Nature Reviews Cancer</i> , 2020, 20, 417-436.	12.8	386
44	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 687-705.	12.5	178
45	Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4682-4687.	3.2	22
46	Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). <i>British Journal of Cancer</i> , 2020, 123, 510-517.	2.9	74
47	Benefit of double-reading cytology smears as a triage strategy among high-risk human papillomavirus-positive women in Mexico. <i>Cancer Cytopathology</i> , 2020, 128, 715-724.	1.4	3
48	What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420). <i>BMC Cancer</i> , 2020, 20, 570.	1.1	37
49	Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening. <i>International Journal of Cancer</i> , 2020, 147, 1864-1873.	2.3	16
50	Young adulthood body mass index, adult weight gain and breast cancer risk: the PROCAS Study (United Kingdom). <i>BMJ</i> , 2020, 370, n1111.	2.9	21
51	Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1281-1297.	1.4	55
52	Population-level impact of human papillomavirus vaccination. <i>Lancet, The</i> , 2020, 395, 412.	6.3	0
53	Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk. <i>Annals of Neurology</i> , 2020, 87, 599-608.	2.8	21
54	Risk Models for Breast Cancer and Their Validation. <i>Statistical Science</i> , 2020, 35, 14-30.	1.6	37

#	ARTICLE	IF	CITATIONS
55	Comparison of StemPrintER, a novel biology-based genomic predictor of distant recurrence in breast cancer, with Oncotype DX in the TransATAC cohort.. Journal of Clinical Oncology, 2020, 38, 1020-1020.	0.8	0
56	External validation of a mammographic texture marker for breast cancer risk in a case-control study. Journal of Medical Imaging, 2020, 7, 1.	0.8	3
57	Tranexamic acid for acute gastrointestinal bleeding (the HALT-IT trial): statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial. Trials, 2019, 20, 467.	0.7	12
58	Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping. Clinical Epigenetics, 2019, 11, 140.	1.8	27
59	The Parkinson's Disease Mendelian Randomization Research Portal. Movement Disorders, 2019, 34, 1864-1872.	2.2	50
60	Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool. JNCI Cancer Spectrum, 2019, 3, pkz066.	1.4	8
61	European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes. Breast Care, 2019, 14, 359-365.	0.8	4
62	Role of HPV Genotype, Multiple Infections, and Viral Load on the Risk of High-Grade Cervical Neoplasia. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1816-1824.	1.1	56
63	A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer. JAMA Oncology, 2019, 5, 1718.	3.4	91
64	A Case-Control Study to Add Volumetric or Clinical Mammographic Density into the Tyrer-Cuzick Breast Cancer Risk Model. Journal of Breast Imaging, 2019, 1, 99-106.	0.5	39
65	Screening performance of abbreviated versions of the UPSIT smell test. Journal of Neurology, 2019, 266, 1897-1906.	1.8	37
66	Predicting late recurrence in ER-positive breast cancer. Nature Reviews Clinical Oncology, 2019, 16, 406-408.	12.5	3
67	Lifestyle behaviours and health measures of women at increased risk of breast cancer taking chemoprevention. European Journal of Cancer Prevention, 2019, 28, 500-506.	0.6	6
68	The percentage of high-grade prostatic adenocarcinoma in prostate biopsies significantly improves on Grade Groups in the prediction of prostate cancer death. Histopathology, 2019, 75, 589-597.	1.6	11
69	Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Research and Treatment, 2019, 176, 377-386.	1.1	61
70	Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. Bone, 2019, 124, 83-88.	1.4	9
71	Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments. Modern Pathology, 2019, 32, 1303-1309.	2.9	25
72	Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants. Breast Cancer Research and Treatment, 2019, 176, 141-148.	1.1	56

#	ARTICLE	IF	CITATIONS
73	Histopathologic False-positive Diagnoses of Prostate Cancer in the Age of Immunohistochemistry. American Journal of Surgical Pathology, 2019, 43, 361-368.	2.1	13
74	A response to "Personalised medicine and population health: breast and ovarian cancer". Human Genetics, 2019, 138, 287-289.	1.8	14
75	Measurement challenge: protocol for international case-control comparison of mammographic measures that predict breast cancer risk. BMJ Open, 2019, 9, e031041.	0.8	14
76	Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico. JAMA Network Open, 2019, 2, e1915781.	2.8	40
77	Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial. International Journal of Cancer, 2019, 144, 2587-2595.	2.3	56
78	Competing Risks for a Diagnosis of Invasive Breast Cancer. JAMA Oncology, 2019, 5, 110.	3.4	0
79	Competing Risks for a Diagnosis of Invasive Breast Cancer"Reply. JAMA Oncology, 2019, 5, 111.	3.4	2
80	Prediction of reader estimates of mammographic density using convolutional neural networks. Journal of Medical Imaging, 2019, 6, 1.	0.8	28
81	Breast Cancer Index and risk stratification in luminal subtypes: A trans-ATAC study.. Journal of Clinical Oncology, 2019, 37, 534-534.	0.8	0
82	Cell cycle progression score differentiates indolent from aggressive prostate cancer in men diagnosed by TURP.. Journal of Clinical Oncology, 2019, 37, e16560-e16560.	0.8	0
83	Molecular progression to cervical precancer, epigenetic switch or sequential model?. International Journal of Cancer, 2018, 143, 1720-1730.	2.3	21
84	Progress in preventive therapy for cancer: a reminiscence and personal viewpoint. British Journal of Cancer, 2018, 118, 1155-1161.	2.9	12
85	Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 310.e7-310.e13.	0.8	19
86	Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density. JAMA Oncology, 2018, 4, e180174.	3.4	148
87	Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. JAMA Oncology, 2018, 4, 545.	3.4	246
88	Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more. International Journal of Cancer, 2018, 143, 333-342.	2.3	16
89	The Value of Helicobacter Eradication in Long-term Aspirin Users. Journal of the National Cancer Institute, 2018, 110, 690-691.	3.0	0
90	Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction. JAMA Oncology, 2018, 4, 476.	3.4	109

#	ARTICLE	IF	CITATIONS
91	Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 633-640.	1.1	17
92	Use of the concordance index for predictors of censored survival data. <i>Statistical Methods in Medical Research</i> , 2018, 27, 2359-2373.	0.7	78
93	RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 58-66.	1.1	3
94	Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 166-175.	3.0	122
95	Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. <i>Journal of Clinical Oncology</i> , 2018, 36, 1941-1948.	0.8	116
96	Prognosis vs Treatment Interaction. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky006.	1.4	7
97	Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review. <i>The Cochrane Library</i> , 2018, , .	1.5	1
98	Outcome measures in clinical trials of treatments for acute severe haemorrhage. <i>Trials</i> , 2018, 19, 533.	0.7	25
99	Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 103.	2.2	7
100	Should reporting of peri-neural invasion and extra prostatic extension be mandatory in prostate cancer biopsies? correlation with outcome in biopsy cases treated conservatively. <i>Oncotarget</i> , 2018, 9, 20555-20562.	0.8	14
101	Exploring the prediction performance for breast cancer risk based on volumetric mammographic density at different thresholds. <i>Breast Cancer Research</i> , 2018, 20, 49.	2.2	8
102	Breast cancer risk in a screening cohort of Asian and white British/Irish women from Manchester UK. <i>BMC Public Health</i> , 2018, 18, 178.	1.2	18
103	A comparison of five methods of measuring mammographic density: a case-control study. <i>Breast Cancer Research</i> , 2018, 20, 10.	2.2	77
104	Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ. <i>British Journal of Cancer</i> , 2018, 119, 36-39.	2.9	13
105	Evaluation of the OncoMasTR prognostic signature in postmenopausal women with primary ER-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 553-553.	0.8	2
106	The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing. <i>JMIR Formative Research</i> , 2018, 2, e24.	0.7	10
107	Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. <i>ELife</i> , 2018, 7, .	2.8	217
108	Overweight and breast cancer risk in the International Breast Cancer Intervention studies I and II. <i>Journal of Clinical Oncology</i> , 2018, 36, 1560-1560.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Residual risk assessment with the Breast Cancer Index (BCI) for prediction of late distant recurrence (DR) in patients from the TransATAC study.. Journal of Clinical Oncology, 2018, 36, 529-529.	0.8	1
110	Using a convolutional neural network to predict readers' estimates of mammographic density for breast cancer risk assessment. , 2018, , .		0
111	Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. Journal of Clinical Oncology, 2017, 35, 743-750.	0.8	58
112	Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPs' attitudes. British Journal of General Practice, 2017, 67, e414-e427.	0.7	33
113	Performance and Diagnostic Accuracy of a Urine-Based Human Papillomavirus Assay in a Referral Population. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1053-1059.	1.1	34
114	The impact of using weight estimated from mammographic images vs. self-reported weight on breast cancer risk calculation. Proceedings of SPIE, 2017, 10134, .	0.8	0
115	The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study. Journal of Medical Genetics, 2017, 54, 111-113.	1.5	56
116	General practitioner attitudes towards prescribing aspirin to carriers of Lynch Syndrome: findings from a national survey. Familial Cancer, 2017, 16, 509-516.	0.9	13
117	HER2 status predicts for upfront AI benefit: AÂTRANS-AIOG meta-analysis of 12,129 patients fromÂATAC, BIG 1-98 and TEAM with centrally determined HER2. European Journal of Cancer, 2017, 79, 129-138.	1.3	21
118	Role of quantitative p16<sup>INK4A</sup> mRNA assay and digital reading of p16<sup>INK4A</sup> immunostained sections in diagnosis of cervical intraepithelial neoplasia. International Journal of Cancer, 2017, 141, 829-836.	2.3	8
119	Estimating efficacy in trials with selective crossover. Statistics in Medicine, 2017, 36, 2333-2346.	0.8	3
120	Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine " A combined analysis of five phase III clinical trials. Papillomavirus Research (Amsterdam, Netherlands), 2017, 3, 105-115.	4.5	22
121	Assessing opportunities for coordinated <sc>R</sc>&<sc>D</sc> in early cancer detection and management in <sc>E</sc>urope. International Journal of Cancer, 2017, 140, 1700-1701.	2.3	1
122	Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet, The, 2017, 390, 2143-2159.	6.3	314
123	Preventive therapy for cancer. Lancet Oncology, The, 2017, 18, e472-e482.	5.1	81
124	Outcomes in Women With Cytology Showing Atypical Squamous Cells of Undetermined Significance With vs Without Human Papillomavirus Testing. JAMA Oncology, 2017, 3, 1327.	3.4	13
125	Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer. Scientific Reports, 2017, 7, 5124.	1.6	17
126	Preventing invasive breast cancer using endocrine therapy. Breast, 2017, 34, S47-S54.	0.9	14



#	ARTICLE	IF	CITATIONS
127	Health Service Accessibility and Risk in Cervical Cancer Prevention: Comparing Rural Versus Nonrural Residence in New Mexico. <i>Journal of Rural Health</i> , 2017, 33, 382-392.	1.6	25
128	Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era. <i>JAMA Oncology</i> , 2017, 3, 833.	3.4	88
129	A novel and fully automated mammographic texture analysis for risk prediction: results from two case-control studies. <i>Breast Cancer Research</i> , 2017, 19, 114.	2.2	34
130	SNPs for breast cancer risk assessment. <i>Oncotarget</i> , 2017, 8, 99211-99212.	0.8	7
131	Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I). <i>Journal of Clinical Oncology</i> , 2017, 35, 2666-2673.	0.8	40
132	Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions. <i>Oncotarget</i> , 2017, 8, 50510-50520.	0.8	22
133	Explaining the Better Prognosis of Screening-Exposed Breast Cancers: Influence of Tumor Characteristics and Treatment. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 479-487.	1.1	10
134	Transitioning to routine breast cancer risk assessment and management in primary care: what can we learn from cardiovascular disease?. <i>Australian Journal of Primary Health</i> , 2016, 22, 255.	0.4	16
135	Population-based prevalence of cervical infection with human papillomavirus genotypes 16 and 18 and other high risk types in Tlaxcala, Mexico. <i>BMC Infectious Diseases</i> , 2016, 16, 461.	1.3	15
136	Breast cancer risk feedback to women in the UK NHS breast screening population. <i>British Journal of Cancer</i> , 2016, 114, 1045-1052.	2.9	73
137	Impact of Screening on Breast Cancer Mortalityâ€”Response. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 873-873.	1.1	0
138	Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome. <i>British Journal of Cancer</i> , 2016, 114, 1078-1083.	2.9	105
139	Impact of Screening on Breast Cancer Mortality: The UK Program 20 Years On. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 455-462.	1.1	79
140	Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 425-432.	1.2	1
141	Validation of a <sc>DNA</sc> methylation <sc>HPV</sc> triage classifier in a screening sample. <i>International Journal of Cancer</i> , 2016, 138, 2745-2751.	2.3	78
142	Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptorâ€”Positive Lymph Nodeâ€”Negative Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5043-5048.	3.2	18
143	Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests). <i>Journal of Clinical Microbiology</i> , 2016, 54, 2337-2342.	1.8	48
144	A comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral populationâ€”PREDICTORS 4. <i>Journal of Clinical Virology</i> , 2016, 82, 145-151.	1.6	16

#	ARTICLE	IF	CITATIONS
145	Need for expanded HPV genotyping for cervical screening. Papillomavirus Research (Amsterdam,) Tj ETQq1 1 0.784314 rgBT /Overloc	4.5	56
146	Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials. Breast Cancer Research and Treatment, 2016, 158, 591-596.	1.1	5
147	Clinician-Reported Barriers to Implementing Breast Cancer Chemoprevention in the UK: A Qualitative Investigation. Public Health Genomics, 2016, 19, 239-249.	0.6	25
148	Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. Journal of the National Cancer Institute, 2016, 108, djw149.	3.0	165
149	Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors. Breast Cancer Research and Treatment, 2016, 159, 71-78.	1.1	11
150	Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics, 2016, 138, .	1.0	84
151	Incidence of multiple myeloma in Great Britain, Sweden, and MalmÅr, Sweden: the impact of differences in case ascertainment on observed incidence trends. BMJ Open, 2016, 6, e009584.	0.8	32
152	Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. Papillomavirus Research (Amsterdam, Netherlands), 2016, 2, 61-69.	4.5	30
153	Ovarian cancer screening: UKCTOCS trial. Lancet, The, 2016, 387, 2602.	6.3	8
154	Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet, The, 2016, 387, 866-873.	6.3	149
155	Cancer Prevention: Obstacles, Challenges, and the Road Ahead. Journal of the National Cancer Institute, 2016, 108, .	3.0	82
156	Differing Perspectives on Breast Cancer Chemoprevention. JAMA Oncology, 2016, 2, 276.	3.4	6
157	iPreventÂ®: a tailored, web-based, decision support tool for breast cancer risk assessment and management. Breast Cancer Research and Treatment, 2016, 156, 171-182.	1.1	33
158	Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. Journal of Clinical Oncology, 2016, 34, 139-143.	0.8	30
159	Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 36-42.	1.1	14
160	HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nature Reviews Clinical Oncology, 2016, 13, 119-132.	12.5	154
161	A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors. Oncotarget, 2016, 7, 71833-71840.	0.8	19
162	Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA Study. Salud Publica De Mexico, 2016, 58, 197-210.	0.1	26

#	ARTICLE	IF	CITATIONS
163	Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study. Programme Grants for Applied Research, 2016, 4, 1-210.	0.4	75
164	Application of active surveillance threshold to series of samples submitted for commercial testing.. Journal of Clinical Oncology, 2016, 34, 84-84.	0.8	0
165	Improved use of clinical variables for prognosis of distant recurrence in patients with ER+ breast cancer treated with 5 years endocrine therapy.. Journal of Clinical Oncology, 2016, 34, 566-566.	0.8	4
166	HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and exitit{EPB41L3} methylation classifier. Cancer Biomarkers, 2015, 15, 669-675.	0.8	44
167	The Interpretive Variability of Cervical Biopsies and Its Relationship to HPV Status. American Journal of Surgical Pathology, 2015, 39, 729-736.	2.1	48
168	Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. Breast Cancer Research, 2015, 17, 147.	2.2	186
169	Visual Inspection after Acetic Acid (VIA) Is Highly Heterogeneous in Primary Cervical Screening in Amazonian Peru. PLoS ONE, 2015, 10, e0115355.	1.1	19
170	Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake. Ecanermedicalscience, 2015, 9, 595.	0.6	20
171	Human papillomavirus testing 2007â€“2012: <scp>C</scp>â€“testing and triage utilization and impact on subsequent clinical management. International Journal of Cancer, 2015, 136, 2854-2863.	2.3	28
172	Impact of preventive therapy on the risk of breast cancer among women with benign breast disease. Breast, 2015, 24, S51-S55.	0.9	31
173	Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. Clinical Cancer Research, 2015, 21, 2763-2770.	3.2	36
174	Performance of the Xpert HPV assay in women attending for cervical screening. Papillomavirus Research (Amsterdam, Netherlands), 2015, 1, 32-37.	4.5	29
175	PSA testing for prostate cancer screening â€“ Authors' reply. Lancet Oncology, The, 2015, 16, e3.	5.1	1
176	Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncology, The, 2015, 16, 67-75.	5.1	349
177	A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. New England Journal of Medicine, 2015, 372, 711-723.	13.9	1,090
178	Markers for the identification of late breast cancer recurrence. Breast Cancer Research, 2015, 17, 10.	2.2	60
179	Detection of Human Papillomavirus 16, 18, and 45 in Women With ASC-US Cytology and the Risk of Cervical Precancer. American Journal of Clinical Pathology, 2015, 143, 160-167.	0.4	32
180	In Regard to Vaidya etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 92, 954-955.	0.4	4

#	ARTICLE	IF	CITATIONS
181	Gardasil 9 joins the fight against cervix cancer. <i>Expert Review of Vaccines</i> , 2015, 14, 1047-1049.	2.0	42
182	Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 309-318.	1.1	37
183	Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. <i>European Journal of Epidemiology</i> , 2015, 30, 5-18.	2.5	53
184	Background risk of breast cancer and the association between physical activity and mammographic density. <i>Breast Cancer Research</i> , 2015, 17, 50.	2.2	17
185	Update on breast cancer risk prediction and prevention. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 92-97.	0.9	27
186	Human Papillomavirus Oncogenic mRNA Testing for Cervical Cancer Screening. <i>American Journal of Clinical Pathology</i> , 2015, 144, 473-483.	0.4	51
187	Effect of Metformin on Breast Ductal Carcinoma <i>In Situ</i> Proliferation in a Randomized Presurgical Trial. <i>Cancer Prevention Research</i> , 2015, 8, 888-894.	0.7	23
188	Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16. <i>International Journal of Cancer</i> , 2015, 136, E638-45.	2.3	51
189	A concordance index for matched case-control studies with applications in cancer risk. <i>Statistics in Medicine</i> , 2015, 34, 396-405.	0.8	27
190	Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score. <i>Journal of Clinical Oncology</i> , 2015, 33, 916-922.	0.8	189
191	Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16040-e16040.	0.8	1
192	Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 54-54.	0.8	0
193	DNA methylation gene-based models indicating independent poor outcome in prostate cancer. <i>BMC Cancer</i> , 2014, 14, 655.	1.1	22
194	Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I. <i>Breast Cancer Research</i> , 2014, 16, 451.	2.2	74
195	Cervical Screening at Age 50-64 Years and the Risk of Cervical Cancer at Age 65 Years and Older: Population-Based Case Control Study. <i>PLoS Medicine</i> , 2014, 11, e1001585.	3.9	104
196	DNA methylation of <i>PITX2</i> predicts poor survival in men with prostate cancer. <i>Biomarkers in Medicine</i> , 2014, 8, 1143-1150.	0.6	23
197	Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 1460-1468.	5.1	56
198	The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States. <i>International Journal of Cancer</i> , 2014, 135, 624-634.	2.3	36

#	ARTICLE	IF	CITATIONS
199	Breast Cancer Risk in Young Women in the National Breast Screening Programme: Implications for Applying NICE Guidelines for Additional Screening and Chemoprevention. <i>Cancer Prevention Research</i> , 2014, 7, 993-1001.	0.7	37
200	Concurrence of Multiple Human Papillomavirus Infections in a Large US Population-based Cohort. <i>American Journal of Epidemiology</i> , 2014, 180, 1066-1075.	1.6	21
201	Endpoints for the Evaluation of Breast Cancer Treatments. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju323-dju323.	3.0	0
202	A Population-Based Evaluation of Cervical Screening in the United States: 2008-2011. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 765-773.	1.1	50
203	Cervical excisional treatment of young women: A population-based study. <i>Gynecologic Oncology</i> , 2014, 132, 628-635.	0.6	17
204	Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions. <i>Journal of Clinical Virology</i> , 2014, 60, 44-49.	1.6	44
205	Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women. <i>Gynecologic Oncology</i> , 2014, 132, 709-714.	0.6	74
206	Radiotherapy for breast cancer, the TARGIT-A trial. <i>Lancet</i> , The, 2014, 383, 1716.	6.3	48
207	Prognostic Value of a Cell Cycle Progression Score for Men with Prostate Cancer. <i>Recent Results in Cancer Research</i> , 2014, 202, 133-140.	1.8	7
208	Altered Microenvironment Promotes Progression of Preinvasive Breast Cancer: Myoepithelial Expression of $\alpha 6$ Integrin in DCIS Identifies High-risk Patients and Predicts Recurrence. <i>Clinical Cancer Research</i> , 2014, 20, 344-357.	3.2	77
209	Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. <i>Lancet</i> , The, 2014, 383, 1041-1048.	6.3	504
210	A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes. <i>International Journal of Cancer</i> , 2014, 135, 1425-1432.	2.3	51
211	Prevention and early detection of prostate cancer. <i>Lancet Oncology</i> , The, 2014, 15, e484-e492.	5.1	372
212	Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1997-2008.	1.1	137
213	Assessing and managing breast cancer risk: Clinicians' current practice and future needs. <i>Breast</i> , 2014, 23, 644-650.	0.9	44
214	Editorial Comment. <i>Journal of Urology</i> , 2014, 192, 414-414.	0.2	0
215	A comparison of methylation levels in HPV18, HPV31 and HPV33 genomes reveals similar associations with cervical precancers. <i>Journal of Clinical Virology</i> , 2014, 59, 161-166.	1.6	37
216	E17. The prevention of breast cancer. <i>European Journal of Cancer</i> , 2014, 50, S34-S35.	1.3	0

#	ARTICLE	IF	CITATIONS
217	Use of a SNP panel to refine risk estimates in women at high risk of breast cancer: Results from two randomized tamoxifen prevention trials.. Journal of Clinical Oncology, 2014, 32, 1519-1519.	0.8	1
218	Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam).. Journal of Clinical Oncology, 2014, 32, 529-529.	0.8	5
219	Clinical impact of differential risk stratification by breast cancer index (BCI) versus recurrence score (RS) in HR+ early-stage breast cancer: A TransATAC study.. Journal of Clinical Oncology, 2014, 32, 532-532.	0.8	0
220	Validation of an RNA cell cycle progression (CCP) score for predicting prostate cancer death in a conservatively managed needle biopsy cohort.. Journal of Clinical Oncology, 2014, 32, 5059-5059.	0.8	0
221	A population-based study of human papillomavirus genotype prevalence in the United States: Baseline measures prior to mass human papillomavirus vaccination. International Journal of Cancer, 2013, 132, 198-207.	2.3	137
222	The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology: A meta-analysis of the diagnostic accuracy. International Journal of Cancer, 2013, 132, 101-108.	2.3	114
223	Human papillomavirus testing for triage of women with low-grade squamous intraepithelial lesions. International Journal of Cancer, 2013, 132, 959-966.	2.3	23
224	HPV16 L1 and L2 DNA methylation predicts high-grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. International Journal of Cancer, 2013, 133, 637-644.	2.3	56
225	Role of Aspirin in Cancer Prevention. Current Oncology Reports, 2013, 15, 533-540.	1.8	88
226	Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncology, The, 2013, 14, 1067-1076.	5.1	332
227	Comparison of PAM50 Risk of Recurrence Score With OncoDX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy. Journal of Clinical Oncology, 2013, 31, 2783-2790.	0.8	557
228	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, 11-131.	1.7	261
229	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, H1-H31.	1.7	272
230	Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Research and Treatment, 2013, 140, 253-262.	1.1	13
231	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, F1-F31.	1.7	40
232	Comparison of human papillomavirus testing strategies for triage of women referred with low-grade cytological abnormalities. European Journal of Cancer, 2013, 49, 2179-2186.	1.3	29
233	Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. American Journal of Obstetrics and Gynecology, 2013, 208, 184.e1-184.e11.	0.7	154
234	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, G1-G31.	1.7	33

#	ARTICLE	IF	CITATIONS
235	A frailty model for interaction between multiple events. <i>Journal of Multivariate Analysis</i> , 2013, 122, 133-147.	0.5	2
236	Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. <i>Lancet, The</i> , 2013, 381, 1827-1834.	6.3	391
237	Factors Predicting Late Recurrence for Estrogen Receptor-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1504-1511.	3.0	200
238	Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2013, 31, 2942-2962.	0.8	279
239	Prolaris: A novel genetic test for prostate cancer prognosis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5005-5005.	0.8	4
240	Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR+ early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype.. <i>Journal of Clinical Oncology</i> , 2013, 31, 506-506.	0.8	8
241	Development of a tailored, computerized, breast cancer risk assessment and decision support tool: What do clinicians want?. <i>Journal of Clinical Oncology</i> , 2013, 31, e20660-e20660.	0.8	2
242	Assessing breast cancer risk in primary care: What can we learn from cardiovascular disease?. <i>Journal of Clinical Oncology</i> , 2013, 31, 17-17.	0.8	1
243	Development and validation of a multivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort.. <i>Journal of Clinical Oncology</i> , 2013, 31, 67-67.	0.8	3
244	A meta-analysis of endocrine therapy trials in early breast cancer (BC) evaluating the impact of obesity: Are aromatase inhibitors (AIs) optimal therapy in obese ER+ BC?. <i>Journal of Clinical Oncology</i> , 2013, 31, 575-575.	0.8	0
245	Assessing breast cancer risk in primary care: What can we learn from cardiovascular disease?. <i>Journal of Clinical Oncology</i> , 2013, 31, 1559-1559.	0.8	0
246	CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2012, 104, 452-460.	3.0	247
247	Clinical and epidemiological issues in mammographic density. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 33-40.	12.5	98
248	ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. <i>Breast Cancer Research</i> , 2012, 14, R46.	2.2	46
249	Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. <i>Breast Cancer Research</i> , 2012, 14, R57.	2.2	75
250	Breast density predicts endocrine treatment outcome in the adjuvant setting. <i>Breast Cancer Research</i> , 2012, 14, 109.	2.2	5
251	Comparison of Seven Tests for High-Grade Cervical Intraepithelial Neoplasia in Women with Abnormal Smears: the Predictors 2 Study. <i>Journal of Clinical Microbiology</i> , 2012, 50, 1867-1873.	1.8	150
252	Assessing Individual Breast Cancer Risk within the U.K. National Health Service Breast Screening Program: A New Paradigm for Cancer Prevention. <i>Cancer Prevention Research</i> , 2012, 5, 943-951.	0.7	104

#	ARTICLE	IF	CITATIONS
253	Preventive Therapy for Breast Cancer. <i>Current Oncology Reports</i> , 2012, 14, 568-573.	1.8	5
254	New Technologies and Procedures for Cervical Cancer Screening. <i>Vaccine</i> , 2012, 30, F107-F116.	1.7	117
255	Nucleic Acid Tests for the Detection of Alpha Human Papillomaviruses. <i>Vaccine</i> , 2012, 30, F100-F106.	1.7	91
256	Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 625-629.	1.1	30
257	Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4273-4278.	0.8	666
258	Predictive algorithms for adjuvant therapy: TransATAC. <i>Steroids</i> , 2011, 76, 777-780.	0.8	32
259	Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. <i>Lancet Oncology</i> , The, 2011, 12, 21-29.	5.1	476
260	Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. <i>Lancet Oncology</i> , The, 2011, 12, 245-255.	5.1	668
261	Preventive therapy for breast cancer: a consensus statement. <i>Lancet Oncology</i> , The, 2011, 12, 496-503.	5.1	196
262	10-year analysis of the ATAC trial: wrong conclusion? " Authors' reply. <i>Lancet Oncology</i> , The, 2011, 12, 217.	5.1	2
263	Absolute Quantitation of DNA Methylation of 28 Candidate Genes in Prostate Cancer Using Pyrosequencing. <i>Disease Markers</i> , 2011, 30, 151-161.	0.6	74
264	Influence of Comorbidities and Age on Risk of Death Without Recurrence: A Retrospective Analysis of the Arimidex, Tamoxifen Alone or in Combination Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 4266-4272.	0.8	61
265	Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2011, 25, 617-629.	1.4	16
266	Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor-Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical Factors. <i>Journal of Clinical Oncology</i> , 2011, 29, 4365-4372.	0.8	123
267	Tamoxifen-Induced Reduction in Mammographic Density and Breast Cancer Risk Reduction: A Nested Case-Control Study. <i>Journal of the National Cancer Institute</i> , 2011, 103, 744-752.	3.0	358
268	Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. <i>Disease Markers</i> , 2011, 30, 151-61.	0.6	52
269	Long-term cervical cancer prevention strategies across the globe. <i>Gynecologic Oncology</i> , 2010, 117, S11-S14.	0.6	30
270	Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears. <i>Journal of Medical Virology</i> , 2010, 82, 1186-1191.	2.5	32



#	ARTICLE	IF	CITATIONS
271	Reply to M. Rosman et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e648-e648.	0.8	1
272	Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 1829-1834.	0.8	647
273	Controversies in Design and Interpretation of Adjuvant Clinical Trials. <i>Cancer Investigation</i> , 2010, 28, 28-34.	0.6	4
274	Long-term Follow-up in Cancer Prevention Trials (It Ain't Over 'Til It's Over). <i>Cancer Prevention Research</i> , 2010, 3, 689-691.	0.7	20
275	Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen. <i>Journal of Clinical Oncology</i> , 2010, 28, 509-518.	0.8	716
276	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. <i>Lancet Oncology</i> , The, 2010, 11, 1135-1141.	5.1	1,017
277	Breast cancer prevention in the developing world. <i>Breast Cancer Research</i> , 2010, 12, S9.	2.2	9
278	American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. <i>Journal of Clinical Oncology</i> , 2009, 27, 3235-3258.	0.8	254
279	Aromatase Inhibitor-Induced Carpal Tunnel Syndrome: Results From the ATAC Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 4961-4965.	0.8	75
280	Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. <i>International Journal of Cancer</i> , 2009, 124, 516-520.	2.3	557
281	p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer. <i>BJU International</i> , 2009, 104, 20-24.	1.3	39
282	Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. <i>Lancet Oncology</i> , The, 2009, 10, 501-507.	5.1	642
283	Chemoprevention of breast cancer. <i>Breast Cancer</i> , 2008, 15, 10-16.	1.3	27
284	Breast cancer chemoprevention. <i>Oncology Reviews</i> , 2008, 2, 223-228.	0.8	6
285	Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. <i>Cancer</i> , 2008, 112, 69-74.	2.0	65
286	Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology—Results from the Hammersmith study. <i>International Journal of Cancer</i> , 2008, 122, 2294-2300.	2.3	70
287	Aromatase inhibitors in early breast-cancer treatment: The story so far. <i>Breast</i> , 2008, 17, 2-8.	0.9	5
288	Assessing risk for breast cancer. <i>Breast Cancer Research</i> , 2008, 10, S13.	2.2	12

#	ARTICLE	IF	CITATIONS
289	Visually assessed breast density, breast cancer risk and the importance of the craniocaudal view. <i>Breast Cancer Research</i> , 2008, 10, R64.	2.2	44
290	Cervical cancer screening following prophylactic human papillomavirus vaccination. <i>Vaccine</i> , 2008, 26, A16-A23.	1.7	103
291	Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing Countries. <i>Vaccine</i> , 2008, 26, K29-K41.	1.7	526
292	Hormone replacement therapy and the risk of breast cancer. <i>European Journal of Cancer</i> , 2008, 44, 2344-2349.	1.3	41
293	Primary endpoints for randomised trials of cancer therapy. <i>Lancet, The</i> , 2008, 371, 2156-2158.	6.3	34
294	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. <i>Lancet Oncology, The</i> , 2008, 9, 45-53.	5.1	929
295	Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. <i>Lancet Oncology, The</i> , 2008, 9, 937-945.	5.1	170
296	Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. <i>Lancet Oncology, The</i> , 2008, 9, 1143-1148.	5.1	171
297	Comparison of Predictors for High-Grade Cervical Intraepithelial Neoplasia in Women with Abnormal Smears. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 3033-3042.	1.1	208
298	IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1377-1385.	1.1	52
299	Use of LHRH-agonists as adjuvant therapy for breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 1065-1071.	1.5	1
300	Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 1059-1065.	0.8	409
301	Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. <i>BMJ: British Medical Journal</i> , 2008, 337, a1754-a1754.	2.4	525
302	Results at Recruitment From a Randomized Controlled Trial Comparing Human Papillomavirus Testing Alone With Conventional Cytology as the Primary Cervical Cancer Screening Test. <i>Journal of the National Cancer Institute</i> , 2008, 100, 492-501.	3.0	259
303	Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting. <i>Journal of Medical Screening</i> , 2007, 14, 34-42.	1.1	64
304	Surrogate endpoints for cancer screening trials: general principles and an illustration using the UK Flexible Sigmoidoscopy Screening Trial. <i>Journal of Medical Screening</i> , 2007, 14, 178-185.	1.1	32
305	Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 272-282.	3.0	510
306	HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. <i>European Journal of Cancer</i> , 2007, 43, 476-480.	1.3	65

#	ARTICLE	IF	CITATIONS
307	The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer. Expert Review of Anticancer Therapy, 2007, 7, 1089-1094.	1.1	11
308	Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. International Journal of Cancer, 2007, 121, 796-802.	2.3	99
309	The impact of new technologies in cervical cancer screening: Results of the recruitment phase of a large randomised controlled trial from a public health perspective. International Journal of Cancer, 2007, 121, 2729-2734.	2.3	10
310	Estimating the Effect of Treatment in a Proportional Hazards Model in the Presence of Non-Compliance and Contamination. Journal of the Royal Statistical Society Series B: Statistical Methodology, 2007, 69, 565-588.	1.1	42
311	Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading. BJU International, 2007, 100, 1240-1244.	1.3	39
312	Bone versus breast density. Breast Cancer Research, 2006, 8, 104.	2.2	2
313	Human Papillomavirus Testing and Liquid-Based Cytology: Results at Recruitment From the New Technologies for Cervical Cancer Randomized Controlled Trial. Journal of the National Cancer Institute, 2006, 98, 765-774.	3.0	275
314	Chapter 10: New dimensions in cervical cancer screening. Vaccine, 2006, 24, S90-S97.	1.7	95
315	Overview of the European and North American studies on HPV testing in primary cervical cancer screening. International Journal of Cancer, 2006, 119, 1095-1101.	2.3	922
316	Chemoprevention of Breast Cancer. Women's Health, 2006, 2, 853-861.	0.7	1
317	Aromatase Inhibitors for Breast Cancer Prevention. Journal of Clinical Oncology, 2005, 23, 1636-1643.	0.8	175
318	Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating Study. Journal of Clinical Oncology, 2005, 23, 7512-7517.	0.8	248
319	Forest plots and the interpretation of subgroups. Lancet, The, 2005, 365, 1308.	6.3	99
320	Early stopping of clinical trials. Breast Cancer Research, 2005, 7, 181-3.	2.2	7
321	Anastrozole. Drugs of Today, 2005, 41, 227.	2.4	6
322	Tamoxifen and Breast Density in Women at Increased Risk of Breast Cancer. Journal of the National Cancer Institute, 2004, 96, 621-628.	3.0	288
323	A breast cancer prediction model incorporating familial and personal risk factors. Statistics in Medicine, 2004, 23, 1111-1130.	0.8	1,052
324	Epidemiology of breast cancer – selected highlights. Breast, 2003, 12, 405-411.	0.9	34

#	ARTICLE	IF	CITATIONS
325	Treatment of DCIS results from clinical trials. <i>Surgical Oncology</i> , 2003, 12, 213-219.	0.8	29
326	Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomized controlled trial. <i>Lancet, The</i> , 2003, 362, 95-102.	6.3	575
327	Aromatase Inhibitors in Prevention Data from the ATAC (Arimidex, Tamoxifen Alone or in) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.8	81
328	Role of HPV testing in clinical practice. <i>Virus Research</i> , 2002, 89, 263-269.	1.1	35